Updates
Watch for NGN Capital. Look them up. Bier is a highly regarded player for large capital moves with NGN in the industry. AMBS, like every other bio, is at a pivotal point with a partner, financing, licensing, etc. Becton cannot got to the board or shareholders and simple pay AMBS 200m to buy Lympro (as an example), they would have to do it based on valuation and that equates to very small money. Word is that they want to buy it, not just license it. Imagine if AMBS just said that "we don't need you, we have 18 months of operating cash". AMBS has pivotal news on several fronts, still coming for any naysayers. One was supposed to drop by now and hasn't, I suspect there's only a small filing delay. Novartis would come in with sizeable cash up front to use MANF as a platform for their projects and they would hand pick which opportunities they want to go after. Platforms are easier to get speculative valuation on once they wrap arms around all of the diseases. Get PPS up, get valuation, more to come.
I have to note that simply getting angry at my past posts around things not happening the next day, this is a hopeful person that is doing something off of a message board, please don't do that. Let this be a forum for discussion, not to buy, sell or be manipulated. I have led conclusions to 4 events on here, the 4th is ready to drop, It wasn't anything said yet. Keep in mind that dilution is evident in every bio to thrive, AMBS hasn't even touched the edge of standard dilution in a bio by now, to get a no-short clause and other provisions, like an option to force sales at .10, they are playing with their power now, not being prayed upon with others. The company just gave you all 18 months of operations sustained. The largest concerns on this board were just that and yet there's some a little hesitant. That may be the largest news you will get at the end of the day, it staves off bankruptcy, it also opens the door for AMBS to be in control. Keep that close in mind. |
